Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

Lucillia Bezu; Oliver Kepp; Guido Kroemer

doi:10.1080/2162402X.2023.2272352

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

Oncoimmunology. 2023 Nov 9;12(1):2272352. doi: 10.1080/2162402X.2023.2272352. eCollection 2023.

Authors

Lucillia Bezu^{1

2

3}, Oliver Kepp^{1

2}, Guido Kroemer^{1

2

4}

Affiliations

¹ Equipe Labellisée Par La Ligue Contre Le Cancer, Université Paris Cité, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Institut Universitaire de France, Paris, France.
² Metabolomics and Cell Biology Platforms, Villejuif, France.
³ Département d'Anesthésie, Chirurgie et Interventionnel, Gustave Roussy, Villejuif, France.
⁴ Department of Biology, Institut du Cancer Paris CARPEM, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Abstract

Recent clinical trials have compared the use of different chemotherapeutic regimens as "immune induction therapies" to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reputed to be inducers of immunogenic cell death (ICD) appeared to be particularly efficient for this purpose. A trial published in Nature Medicine by Thibaudin et al. reveals the capacity of oxaliplatin-based chemotherapy to sensitize RAS-mutant unresectable metastatic colorectal cancer to ICIs blocking CTLA-4 and PD-L1.

Keywords: Cancer; immunogenic cell death; immunotherapy.

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / genetics
Humans
Immune Checkpoint Inhibitors
Oxaliplatin / pharmacology
Oxaliplatin / therapeutic use

Substances

Immune Checkpoint Inhibitors
Antineoplastic Agents
Oxaliplatin